BioCryst Pharmaceuticals, Inc. (BCRX) 의 후행 P/E는 7.9, 선행 P/E 35.2. 후행 이익수익률은 12.73%, 선행 이익수익률 2.84%. PEG 0.63 (Peter Lynch 저평가 ≤1.0).
이 페이지에서 입증된 기준:
SharesGrow 종합 점수: 80/100 5/7 개 기준 통과.
| Year | P/E (TTM) | PEG 비율 | P/B 비율 | P/S 비율 | 배당 수익률 |
|---|---|---|---|---|---|
| 2016 | -8.5 | -0.31 | -0.82 | 17.70 | - |
| 2017 | -6.3 | -1.58 | -0.66 | 16.46 | - |
| 2018 | -8.2 | -0.32 | -1.14 | 40.32 | - |
| 2019 | -3.7 | 0.90 | 10.43 | 8.17 | - |
| 2020 | -6.8 | -0.43 | -64.69 | 69.96 | - |
| 2021 | -13.5 | 2.45 | -23.19 | 15.78 | - |
| 2022 | -8.6 | -0.30 | -7.24 | 7.88 | - |
| 2023 | -5.1 | 0.45 | -2.53 | 3.47 | - |
| 2024 | -17.5 | 0.28 | -3.27 | 3.45 | - |
| 2025 | 6.2 | -0.02 | -13.74 | 1.87 | - |
| Year | EPS (희석) | 매출 | 순이익 | 순이익률 |
|---|---|---|---|---|
| 2016 | $-0.75 | $26.35M | $-55.14M | -209.3% |
| 2017 | $-0.78 | $25.19M | $-65.78M | -261.2% |
| 2018 | $-0.98 | $20.65M | $-101.25M | -490.3% |
| 2019 | $-1.04 | $48.84M | $-120.07M | -245.9% |
| 2020 | $-1.09 | $17.81M | $-182.81M | -1026.4% |
| 2021 | $-1.03 | $157.17M | $-184.06M | -117.1% |
| 2022 | $-1.33 | $270.83M | $-247.12M | -91.2% |
| 2023 | $-1.18 | $331.41M | $-226.54M | -68.4% |
| 2024 | $-0.43 | $450.71M | $-88.88M | -19.7% |
| 2025 | $1.21 | $874.84M | $263.86M | 30.2% |
| Year | EPS (평균) | EPS 범위 | 매출 (평균) | 매출 범위 | 애널리스트 수 |
|---|---|---|---|---|---|
| 2026 | $0.27 | $0.12 – $0.36 | $650.76M | $647.36M – $654.16M | 5 |
| 2027 | $0.47 | $0.20 – $0.86 | $739.47M | $706.89M – $772.04M | 5 |
| 2028 | $0.46 | $0.15 – $0.68 | $874.88M | $862.28M – $887.47M | 4 |
| 2029 | $1.02 | $0.97 – $1.07 | $1.08B | $1.04B – $1.12B | 2 |
| 2030 | $1.63 | $1.56 – $1.72 | $1.3B | $1.25B – $1.35B | 2 |
